Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.37 |
| ▸ | FURIN | P09958 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | CPA2 | P48052 | 1/20 | 0.36 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14669796 | 0.95 | NMT2 (0.38) | FOLH1CPB2NMT2NMT1FURIN | |
| SCHEMBL14669549 | 0.92 | GNPAT (0.45) | FOLH1CPB2FURINCPA1CPA2 | |
| SCHEMBL14669746 | 0.92 | GNPAT (0.45) | FOLH1CPB2FURINCPA1CPA2 | |
| SCHEMBL14669948 | 0.88 | FOLH1 (0.49) | FOLH1CPB2NMT2NMT1SLC6A5 | |
| SCHEMBL16340703 | 0.87 | NMT2 (0.37) | FOLH1CPB2NMT2NMT1FURIN | |
| SCHEMBL14669806 | 0.85 | SLC6A5 (0.56) | NMT2NMT1SLC6A5 | |
| SCHEMBL16340673 | 0.83 | NMT2 (0.38) | CPB2NMT2NMT1FURIN | |
| SCHEMBL9716627 | 0.82 | FOLH1 (0.58) | FOLH1CPB2NMT2NMT1SLC15A2 | |
| SCHEMBL9716630 | 0.82 | FOLH1 (0.58) | FOLH1CPB2NMT2NMT1SLC15A2 | |
| SCHEMBL29398096 | 0.81 | GNPAT (0.53) | FOLH1CPB2FURINCPA1CPA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029920-A1 | Metal Nanoparticles | BRIMBLE MARGARET A (NZ) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029920-A1 | Metal Nanoparticles | PSTPIP2, PCNP, ANPEP | FOLH1 352/4885CPB2 230/4885NMT2 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.